Combo Therapy for Advanced NSCLC Provides PFS Benefit Combo Therapy for Advanced NSCLC Provides PFS Benefit

Combining a TKI with chemo or an antiangiogenic agent may prolong PFS in advanced NSCLC with certain mutations. The study was published as a preprint and has not yet been peer reviewed.First Look
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news